PHAR (Pharming Group) Valuation Rank


PHAR Pharming Group PHAR
76 GF Score
Price $13.34
GF Value $14.42
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pharming Group Valuation Rank Related Terms

PHAR
76GF Score
Pharming Group PHAR
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.34 is trading 7.5% below its estimated GF Value™ of $14.42. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Valuation Rank:
  • GF Value™: $14.42 vs. price of $13.34 (7.5% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
76GF Score

Get the complete analysis for PHAR

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.34
Price
$14.42
GF Value